Brief: Mateon, Asili Research Alliance Enter Partnership For Development Of Artemisinin Against Covid-19
20/07/2020 12:07
July 20 (Reuters) - Mateon Therapeutics Inc MATN.PK :
* MATEON AND ASILI RESEARCH ALLIANCE ENTER INTO PARTNERSHIP
FOR
THE DEVELOPMENT OF ARTEMISININ AGAINST COVID-19
* MATEON THERAPEUTICS - LAUNCH OF ITS GLOBAL OBSERVATIONAL
STUDY
CALLED ARTI-19 IN PARTNERSHIP WITH ASILI RESEARCH ALLIANCE OF
TANZANIA
Source text for Eikon: ID:nGNXbwGgGG
Further company coverage: MATN.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas